Teva, Intel partner on machine-learning tech for Huntington's Disease ZDNet

Israeli pharmaceutical firm Teva is partnering with US chipmaker Intel to develop wearables and a machine-learning platform that can be used in the treatment of Huntington's Disease. Huntington's is a genetic and typically fatal neurodegenerative disease that causes nerve cells in the brain to deteriorate. This leads to a host of behavioral and psychological problems, including involuntary writhing movements called chorea. There is no cure for Huntington's, but Teva and Intel hope to spur the development of next-generation treatment options by better understanding the progression of the disease and how current treatments impact a patients' quality of life. The companies plan to accomplish this by combining Intel's capabilities in analytics and algorithms with Teva's work around Huntington's treatment and research.